Bliss GVS Pharma's Q1 FY 2025-26 Quarterly Results

Result Summary

• Bliss GVS Pharma Ltd reported a 19.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 29.4%.
• Its expenses for the quarter were up by 0.7% QoQ and 14.0% YoY.
• The net profit decreased 1001.6% QoQ and increased 100.6% YoY.
• The earnings per share (EPS) of Bliss GVS Pharma Ltd stood at 4 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Bliss GVS Pharma Ltd is a pharmaceutical company that operates primarily in the healthcare and pharmaceuticals sector. The company is known for its diverse range of pharmaceutical products, including formulations and active pharmaceutical ingredients (APIs). Typically, pharmaceutical companies focus on the development, manufacturing, and marketing of medications for both domestic and international markets. Recent developments specific to Bliss GVS Pharma Ltd, such as new product launches or strategic partnerships, are not detailed in the provided data.

Revenue

In the first quarter of fiscal year 2026 (Q1FY26), Bliss GVS Pharma Ltd reported a total income of ₹242.92 crores. This represents a significant increase both on a quarter-over-quarter (QoQ) and year-over-year (YoY) basis. Compared to the previous quarter (Q4FY25), the total income rose by 19.2%, climbing from ₹203.73 crores. When compared to the same quarter in the previous year (Q1FY25), the total income increased by 29.4% from ₹187.77 crores. These figures indicate a robust growth in revenue over both the quarter and the year.

Profitability

The company's profitability saw a dramatic turnaround in Q1FY26. Profit before tax surged to ₹63.11 crores, a significant recovery from a loss of ₹3.95 crores in Q4FY25. This represents a quarter-over-quarter improvement of 1697.7%. Year-over-year, the profit before tax increased by 109.9% from ₹30.07 crores in Q1FY25. After accounting for tax expenses of ₹18.75 crores, the profit after tax for Q1FY26 was ₹44.36 crores, contrasting sharply with a loss of ₹4.92 crores in the previous quarter. Compared to Q1FY25, the profit after tax grew by 100.6% from ₹22.11 crores. Earnings per share (EPS) also improved significantly, reaching ₹4.00 in Q1FY26 from a negative ₹0.90 in Q4FY25, reflecting a 544.4% increase QoQ. Year-over-year, EPS increased by 110.5% from ₹1.90.

Operating Metrics

Total expenses for Bliss GVS Pharma Ltd in Q1FY26 amounted to ₹179.81 crores, a slight increase of 0.7% compared to Q4FY25, where expenses were ₹178.48 crores. On a year-over-year basis, total expenses rose by 14.0% from ₹157.69 crores in Q1FY25. The tax expense in Q1FY26 was ₹18.75 crores, which marks a notable increase from both the immediate previous quarter and the same quarter in the previous year, with QoQ and YoY changes of 1853.1% and 135.3%, respectively. These metrics highlight significant changes in the company's operating costs and tax obligations over the period.